当前位置: 首页 >> 检索结果
1. Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.
作者: Emmanuel Feroldi.;Mark J Mulligan.;Kawsar R Talaat.;Chen Sabrina Tan.;Kristopher Paolino.;Srilatha Edupuganti.;Matthew H Collins.;Sarah L George.;Matthew Davis.;Brandon Essink.;Robert Jeanfreau.;James Peterson.;David Fried.;Ada-Maria Minutello.;Sandrine Orlando.;Joanna Korejwo.;Andrey Rojas.;Marine Dufournet.;Tifany Machabert.;Louis Devlin.;Carina Frago.; .
来源: N Engl J Med. 2026年394卷14期1399-1408页
A next-generation, live-attenuated yellow fever vaccine, vYF, was developed in Vero cells to improve vaccine supply and availability. The safety of and immune response to vYF as compared with those of the licensed yellow fever vaccine, YF-VAX, are unclear.
2. A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.
作者: David J Kuter.;Katsuhiro Miura.;Andrea Patriarca.;Dražen Pulanić.;Atanas Radinoff.;Katya Sapunarova.;Antonia Syrigou.;Renchi Yang.;Van Anh Nguyen.;Emily Skelton.;Scarlett Wang.;Donald L Yee.;Parth Patwari.; .
来源: N Engl J Med. 2026年394卷14期1388-1398页
Immune thrombocytopenia (ITP) is a disorder of increased platelet destruction and reduced platelet production and is associated with an increased bleeding risk and a compromised quality of life. Available therapies are ineffective in at least 20% of cases. Mezagitamab is an anti-CD38 antibody that targets plasma cells, plasmablasts, and natural killer cells.
3. Multifaceted Strategies for Hypertension Control in Low-Income Patients.
作者: Katherine T Mills.;Marie Krousel-Wood.;Erin M Peacock.;Jing Chen.;Farah Allouch.;Amy K Carreras.;Siyi Geng.;Alecia Cyprian.;Gerrelda Davis.;Sonja R Fuqua.;Darie Gilliam.;Angelique Greer.;Tammy Mitchell.;Wylea Gray-Winfrey.;Shondra Williams.;Gary M Wiltz.;Keith L Winfrey.;Hua He.;Paul K Whelton.;Jiang He.
来源: N Engl J Med. 2026年394卷14期1376-1387页
Uncontrolled hypertension disproportionately affects populations that have substantial health disparities. Data regarding the effectiveness and implementation of multifaceted, team-based strategies for hypertension control among low-income patients are lacking.
4. CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.
作者: Haydar Frangoul.;Rabi Hanna.;Mark C Walters.;Roy L Kao.;Clinton Carroll.;Meghann McManus.;Kai-Hsin Chang.;Michael C Jaskolka.;Keunpyo Kim.;Qifeng Yu.;Nnenna Badamosi.;Baisong Mei.;Olubunmi Afonja.;Alexis Thompson.; .
来源: N Engl J Med. 2026年394卷13期1292-1301页
Renizgamglogene autogedtemcel (reni-cel) is an investigational clustered regularly interspaced short palindromic repeats (CRISPR)-Cas12a gene-edited autologous hematopoietic stem-cell therapy. The therapy was designed to disrupt the BCL11A binding sites in the HBG1 and HBG2 promoters to reactivate fetal hemoglobin production for the treatment of transfusion-dependent β-thalassemia.
5. CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.
作者: Rabi Hanna.;Haydar Frangoul.;Luis Pineiro.;Christopher McKinney.;Markus Mapara.;Jignesh Dalal.;Hemalatha G Rangarajan.;Harold Atkins.;Akshay Sharma.;Kai-Hsin Chang.;Michael C Jaskolka.;Keunpyo Kim.;Qifeng Yu.;Baisong Mei.;Olubunmi Afonja.;Mark C Walters.; .
来源: N Engl J Med. 2026年394卷13期1281-1291页
Renizgamglogene autogedtemcel (reni-cel) is an investigational clustered regularly interspaced short palindromic repeats (CRISPR)-Cas12a gene-edited autologous hematopoietic stem-cell therapy. The therapy was designed to disrupt the BCL11A binding sites in the HBG1 and HBG2 promoters to reactivate fetal hemoglobin production for the treatment of sickle cell disease.
6. Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.
作者: Ki Hong Choi.;Danbee Kang.;Weon Kim.;Joon-Hyung Doh.;Juhan Kim.;Yong Hwan Park.;Sung Gyun Ahn.;Jong Pil Park.;Sang Min Kim.;Byung Ryul Cho.;Chang-Wook Nam.;Jang Hyun Cho.;Seung-Jae Joo.;Jon Suh.;Jin-Ok Jeong.;Woo Jin Jang.;Choong Won Goh.;Chang-Hwan Yoon.;Jin-Yong Hwang.;Seong-Hoon Lim.;Sang Rok Lee.;Eun-Seok Shin.;Byung Jin Kim.;Cheol Woong Yu.;Sung-Ho Her.;Hyun Kuk Kim.;Kyu Tae Park.;Juwon Kim.;Jihoon Kim.;Taek Kyu Park.;Joo Myung Lee.;Juhee Cho.;Jeong Hoon Yang.;Young Bin Song.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Eliseo Guallar.;Joo-Yong Hahn.; .
来源: N Engl J Med. 2026年394卷13期1302-1312页
The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary coronary-artery reperfusion and secondary prevention interventions.
7. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.
作者: Yong-Joon Lee.;Seung-Jun Lee.;Jin Won Kim.;Sang-Hyup Lee.;Gwang-Sil Kim.;Jae Hyoung Park.;Jin-Man Cho.;Woong Chol Kang.;Hyuck-Jun Yoon.;Won Ho Kim.;Seung-Jin Lee.;Jin Bae Lee.;Ji-Yong Jang.;Sanghoon Shin.;Ik Hyun Park.;Sung Uk Kwon.;Sunwon Kim.;Sung-Jin Hong.;Chul-Min Ahn.;Jung-Sun Kim.;Young-Guk Ko.;Donghoon Choi.;Myeong-Ki Hong.;Yangsoo Jang.;Byeong-Keuk Kim.; .
来源: N Engl J Med. 2026年394卷14期1365-1375页
Despite guideline recommendations, evidence from randomized trials evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic cardiovascular disease remains limited.
8. Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.
作者: Duk-Hyun Kang.;Sung-Ji Park.;Ga Yun Kim.;Sahmin Lee.;Byung Joo Sun.;Joon Bum Kim.;Sung-Ho Jung.;Hyung-Kwan Kim.;Sung-Cheol Yun.;Geu-Ru Hong.;Jong-Min Song.;Cheol-Hyun Chung.
来源: N Engl J Med. 2026年394卷12期1167-1174页
Among asymptomatic patients with severe aortic stenosis, a previous analysis showed that the risk of a composite of death during surgery or within 30 days after surgery (called operative mortality) or death from cardiovascular causes was significantly lower with early surgery than with conservative care. However, the long-term survival benefit of early surgery, as compared with conservative care, remains unclear.
9. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.
作者: Frank A Sinicrope.;Fang-Shu Ou.;Dirk Arnold.;Walter R Peters.;Robert J Behrens.;Christopher H Lieu.;Khalid Matin.;Deirdre J Cohen.;Samara L Potter.;Andrew B Nixon.;Lisa A Kottschade.;Emily Kathol.;Wendy L Frankel.;Ardaman Shergill.;Dennis Hsu.;Anke Reinacher-Schick.;Paul Mehan.;Philip J Gold.;Maged F Khalil.;Tyler Zemla.;Clare Gatten.;Eileen M O'Reilly.;Jeffrey A Meyerhardt.
来源: N Engl J Med. 2026年394卷12期1155-1166页
Standard adjuvant chemotherapy for stage III colon cancer consists of a fluoropyrimidine-plus-oxaliplatin regimen. Whether the addition of atezolizumab (an anti-programmed death ligand 1 agent) to a modified FOLFOX6 regimen (fluorouracil, oxaliplatin, and leucovorin; called mFOLFOX6) would improve outcomes in patients with stage III colon cancer with mismatch repair-deficient (dMMR) status is unclear.
10. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
作者: Wungki Park.;Anup Kasi.;Alexander I Spira.;Luis Paz-Ares Rodríguez.;Benjamin O Herzberg.;Meredith S Pelster.;Anthony W Tolcher.;Yasutoshi Kuboki.;Shigehisa Kitano.;Hirokazu Shoji.;Judy S Wang.;Jordan D Berlin.;Antoine Hollebecque.;Patricia LoRusso.;Christos Fountzilas.;Philippe A Cassier.;Tomohiro Nishina.;Daisuke Sakai.;Chiaki Inagaki.;Daniel Morgensztern.;Makoto Ueno.;Minkyu Jung.;Sang-We Kim.;Pasi A Jänne.;Antoine Italiano.;Benoît You.;T Macarulla.;Hisaki Fujii.;Aditya Shetty.;Ying Lu.;Daniel Cui.;Shilpa Kadam.;Stanley C Gill.;Junko Toyoshima.;Takeshi Saito.;Jonathan W Goldman.
来源: N Engl J Med. 2026年394卷14期1409-1420页
The KRAS p.G12D variant occurs in 5% of patients with non-small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, but no targeted therapies directed against this variant are currently approved for clinical use. Setidegrasib (ASP3082) is a first-in-class KRAS G12D-targeted protein degrader.
11. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
作者: Ann Marie Navar.;Elina Mikhailova.;Alberico L Catapano.;Puja Banka.;Dirk J Blom.;Alberto Cadena.;Susan Kourpanidis.;Norman E Lepor.;Kazuhisa Tsukamoto.;Geraldine Mendizabal.;Julio Nunez.;Wenjuan Zhang.;Pengfei Zhu.;Min Zhuo.;Christie M Ballantyne.; .
来源: N Engl J Med. 2026年394卷6期529-539页
Enlicitide decanoate, an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data are needed.
12. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation.
作者: Ulf Landmesser.;Carsten Skurk.;Paulus Kirchhof.;Thorsten Lewalter.;Johannes Hartung.;Andi Rroku.;Burkert Pieske.;Johannes Brachmann.;Ibrahim Akin.;Claudius Jacobshagen.;Benjamin Meder.;Andreas Zeiher.;Stefan D Anker.;Holger Thiele.;Stefan Blankenberg.;Steffen Massberg.;Heribert Schunkert.;Norbert Frey.;Alexander Joost.;Martin Bergmann.;Ralph Stephan von Bardeleben.;Tim Friede.;Marius Placzek.;Anna Suling.;Karl Georg Haeusler.;Matthias Endres.;Karl Wegscheider.;Leif-Hendrik Boldt.;Ingo Eitel.; .
来源: N Engl J Med. 2026年394卷13期1270-1280页
Catheter-based closure of the left atrial appendage is an alternative to oral anticoagulation for stroke prevention in patients with atrial fibrillation. The effectiveness of this strategy, as compared with physician-directed best medical care, in patients at high risk for stroke and bleeding is unknown.
13. Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.
作者: Hanny Al-Samkari.;César Muñoz.;Çağlayan Geredeli.;Ippokratis Korantzis.;Beatriz González Astorga.;Cagatay Arslan.;Johnny Francisco Cordeiro Camargo.;Florian Scotté.;Giuliano Borges.;Kejia Wang.;Melissa Eisen.;David J Kuter.;Gerald A Soff.
来源: N Engl J Med. 2026年394卷11期1061-1073页
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse outcomes. No widely available therapies are approved for CIT.
14. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
作者: Lana A Castellucci.;Vivien M Chen.;Michael J Kovacs.;Alejandro Lazo-Langner.;Peter Greenstreet.;Susan Kahn.;Benoit Côté.;Sam Schulman.;Kerstin de Wit.;James Douketis.;Deepa Suryanarayan.;Tony Wan.;Erik Yeo.;Genevieve Le Templier.;Huyen A Tran.;Abbey Willcox.;Helen J Crowther.;Ritam Prasad.;Sudeep Shivakumar.;Etimbuk Umana.;Fionnuala Ni Ainle.;Tobias Tritschler.;Stefano Barco.;Jean-Philippe Galanaud.;Marc Blondon.;Lisa Baumann Kreuziger.;Susan Solymoss.;Clive Kearon.;Erin Thomas.;Tim Ramsay.;Gregoire Le Gal.;Marc Rodger.; .
来源: N Engl J Med. 2026年394卷11期1051-1060页
Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two medications.
15. Zorevunersen in Children and Adolescents with Dravet Syndrome.
作者: Linda Laux.;Joseph Sullivan.;M Scott Perry.;Andreas Brunklaus.;Archana Desurkar.;John M Schreiber.;Colin M Roberts.;Kelly G Knupp.;James W Wheless.;Elaine C Wirrell.;Pam Ventola.;Fei Wang.; Meena.;Jessie Lynch.;Kimberly A Parkerson.;Barry Ticho.;J Helen Cross.; .
来源: N Engl J Med. 2026年394卷10期969-982页
Dravet syndrome is a severe developmental and epileptic encephalopathy caused primarily by SCN1A haploinsufficiency. Risks of sudden unexpected death in epilepsy and cognitive deficits are higher among patients with this syndrome than in the general population with epilepsy. The effects of zorevunersen, an antisense oligonucleotide designed to up-regulate NaV1.1 sodium channels, in patients with Dravet syndrome are not known.
16. Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.
作者: Guo-Ming Shi.;Xiao-Yong Huang.;Fei Liang.;Xiao Liang.;Rui Dong.;Qing-Hai Ye.;Qiang Gao.;Yuan Ji.;Zheng-Ping Yu.;Wen-Long Zhai.;Jia-Cheng Lu.;Xiao-Wu Li.;Fu-Bao Liu.;Kui Wang.;Wei Yang.;Jia-Lin Zhang.;Zhi-Qiang Hu.;Shuang-Jian Qiu.;Xiao-Ying Wang.;Xin-Rong Yang.;Hui-Chuan Sun.;Ying-Hong Shi.;Zhen-Bin Ding.;Wei-Ren Liu.;Xiao-Wu Huang.;Cheng Huang.;Ying-Hao Shen.;Jian Sun.;Yi-Feng He.;Yuan-Fei Peng.;Yang Xu.;Jian-Jun Zou.;Jian Zhou.;Jia Fan.; .
来源: N Engl J Med. 2026年394卷10期983-995页
No neoadjuvant treatment has been considered to be standard therapy for patients with resectable intrahepatic cholangiocarcinoma with high-risk factors for recurrence. The GOLP regimen (gemcitabine-oxaliplatin, lenvatinib, and an anti-programmed death 1 antibody) has shown promising efficacy with a manageable safety profile in advanced intrahepatic cholangiocarcinoma and biliary tract cancer.
17. Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
作者: Hiddo J L Heerspink.;Andreas L Birkenfeld.;David Z I Cherney.;Helen M Colhoun.;Per-Henrik Groop.;Linong Ji.;Niels Jongs.;Chantal Mathieu.;Richard E Pratley.;Sylvia E Rosas.;Peter Rossing.;Jay S Skyler.;Katherine R Tuttle.;Robert Lawatscheck.;Meike Brinker.;Markus F Scheerer.;Julie Russell.;Patrick Schloemer.;Janet B McGill.; .
来源: N Engl J Med. 2026年394卷10期947-957页
The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The efficacy and safety of finerenone in persons with type 1 diabetes and CKD are unknown.
18. Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.
作者: Ecaterina E Dumbrava.;Geoffrey I Shapiro.;Aparna R Parikh.;Melissa L Johnson.;Anthony W Tolcher.;John A Thompson.;Anthony B El-Khoueiry.;Andrae L Vandross.;Shivaani Kummar.;Dale R Shepard.;Kim LeDuke.;Lisa Sheehan.;Leila Alland.;Arshad Haque.;Deepika Jalota.;Marc Fellous.;Alison M Schram.
来源: N Engl J Med. 2026年394卷9期872-883页
Rezatapopt is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to Y220C-mutated p53, which stabilizes p53 in its wild-type conformation and restores its functionality.
19. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
作者: Christof Vulsteke.;Nabil Adra.;Pongwut Danchaivijitr.;Maksym Sabadash.;Alejo Rodriguez-Vida.;Zhentao Zhang.;Vagif Atduev.;Y Emre Göger.;Steffen Rausch.;Seok-Ho Kang.;Yohann Loriot.;Jens Bedke.;Matthew D Galsky.;Peter H O'Donnell.;Gunhild von Amsberg.;Nimira Alimohamed.;Grzegorz Sulimka.;Shilpa Gupta.;Viktor Paramonov.;Keita Nakane.;Michael Mihm.;Changting Meng.;Caizhi David Huang.;Chethan Ramamurthy.;Blanca Homet Moreno.;Anders Ullén.; .
来源: N Engl J Med. 2026年394卷13期1257-1269页
Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. Perioperative therapy may improve outcomes in this population.
20. An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.
作者: Nicholas E Johnson.;Li-Jung Tai.;Johanna I Hamel.;John W Day.;Jeffrey M Statland.;Payam Soltanzadeh.;Sankarasubramoney H Subramony.;Charles A Thornton.;W David Arnold.;Matthew Wicklund.;Miriam L Freimer.;Kate Eichinger.;Jeanne Dekdebrun.;Chao-Yin Chen.;Varun Goel.;Bradley McEvoy.;Yiming Zhu.;Steven G Hughes.;Elizabeth J Ackermann.;Arthur A Levin.
来源: N Engl J Med. 2026年394卷8期763-772页
Myotonic dystrophy type 1 is a rare, dominantly inherited, progressive, disabling, neuromuscular disease that leads to decreased life expectancy and has no approved therapies. The disease is caused by a trinucleotide repeat expansion in DMPK, which encodes myotonic dystrophy type 1 protein kinase and imparts a toxic gain of function to the transcribed messenger RNA (mRNA), resulting in dysregulated alternative splicing (missplicing). Delpacibart etedesiran (del-desiran [AOC 1001]) is a monoclonal antibody-oligonucleotide conjugate. The antibody component targets transferrin receptor 1, and the oligonucleotide component targets DMPK mRNA.
|